Sign up Australia
Proactive Investors - Run By Investors For Investors

Clinuvel Pharmaceuticals 21% share spike prompts ASX price query

Clinuvel Pharmaceuticals 21% share spike prompts ASX price query

Clinuvel Pharmaceuticals (ASX: CUV) has received a price and volume query from the ASX after its shares jumped to A$1.92 yesterday, 12 January, up from $1.58 at the close of trading on Friday 6 January.

The company responded to the ASX saying it is not aware of any material information that has not been disclosed to the market, which may explain the sudden investor interest.

However, Clinuvel did refer to its recent announcements in November and December of positive results from its Phase II U.S. clinical trial and its pivotal Phase III European clinical trial.

Both studies related to the company’s lead indication (erythropoietic protoporphyria) for its first-in-class drug SCENESSE® (afamelanotide).

SCENESSE® is being developed as a treatment for people suffering from a loss of melanin production resulting in white or off-white depigmented skin lesions on different parts of the body.

Clinuvel is also finalising a Marketing Authorisation Application for SCENESSE® for submission to the European Medicines Agency within the next few weeks.

An approved MAA would allow the company to market SCENESSE® across the European Union.

Register here to be notified of future CUV Company articles
View full CUV profile

Clinuvel Pharmaceuticals Timeline

Related Articles

March 23 2016
e-Therapeutics is now targeting partners to accelerate the development of its drug discovery engine and commercialise compounds.
February 07 2017
The hybrid pharma services and drug development group has hit some key milestones over this year as trial results are eyed.
January 19 2017
Turnover was £40.4mln in the six months to December

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.